Sun Pharma's IL-23 inhibitor tildrakizumab gains a psoriatic arthritis indication; the announcement cited no phase 3 efficacy figures.
|Articles|August 1, 2011
- Pharmaceutical Executive-08-01-2011
- Volume 0
- Issue 0
Pharmaceutical Executive Digital Edition - August 2011
Carrying the Weight of the Future
Advertisement
Articles in this issue
about 15 years ago
Is the 'Emerging Market' a Dated Concept?about 15 years ago
Innovation at Pfizerabout 15 years ago
Mind the Gap!about 15 years ago
Giving Press Releases New Legsabout 15 years ago
An IOU to Big Pharma Regarding EHRabout 15 years ago
Options for Paying for Health—The Right Wayabout 15 years ago
The Supremes Shape Pharmaabout 15 years ago
Serbia: Ready to Flourishabout 15 years ago
Employers: Fighting Non-Adherenceabout 15 years ago
Europe in HTA GridlockAdvertisement
Related to this article
Brox.AI's co-founder and CEO on why telling an AI to pretend to be a doctor isn’t the same as cloning one — and why that distinction matters for pharma.
Shionogi’s Dr. Draica on why mild COVID-19 still matters, how XOCOVA blocks replication before symptoms, and why prevention beats treatment.
Earlier pediatric planning, innovative trial design, and closer collaboration among regulators, industry, and families are needed to close the persistent gap between the evidence available for adult and pediatric treatments.
BioMarin licenses long-acting Fabry enzyme replacement therapy HM15421/GC1134A, while Ferring agrees to acquire fertility biotech Gameto.
As AI accelerates drug discovery, the industry’s next challenge is building a connected, standards-based data infrastructure capable of supporting it through clinical development.
Shionogi’s Dr. Draica on why mild COVID-19 can worsen chronic conditions for up to a year — and why prevention matters more than hospitalization data suggests.
Brock.AI’s Hamish Brocklebank on recruiting 8% of all US pancreatic cancer prescribers — paying $2,000 an hour, offering equity, and triple opt-in consent.
Advertisement
Advertisement
Trending on PharmExec
1
Bristol Myers Squibb Discloses Patient Death in CAR-T Multiple Sclerosis Trial
2
Roundup: BioMarin Licenses Long-Acting Fabry Enzyme Therapy for $70 Million Upfront, Ferring to Acquire Fertility Biotech Gameto in Deal Worth Up to $1.38 Billion
3
FDA Approves Ilumya for Adults With Active Psoriatic Arthritis
4
Closing the Pediatric Evidence Gap
5